Key Events This Week
15 Sep: Stock declines 3.73% amid technical momentum shift
16 Sep: Intraday high reached with 7.32% surge
17 Sep: Mojo Grade upgraded to Buy following strong financials
18 Sep: Continued gains close week at Rs.1,769.40 (+3.83%)
15 September 2026: Technical Momentum Shifts Amid Price Decline
On 15 September, Tatva Chintan Pharma Chem Ltd’s stock price fell 3.73% to close at Rs.1,545.80, underperforming the Sensex which declined 1.69%. This drop followed a downgrade in the company’s technical grade from bullish to mildly bullish, reflecting a cautious market stance. Despite the decline, longer-term indicators such as weekly and monthly MACD and KST remained bullish, suggesting underlying momentum. The Relative Strength Index (RSI) showed neutrality, indicating no clear overbought or oversold conditions. The mixed technical signals, including mildly bearish Dow Theory and On-Balance Volume (OBV) weekly readings, contributed to a more conservative outlook.
16 September 2026: Strong Intraday Rally Signals Rebound
The stock rebounded sharply on 16 September, surging 6.36% to close at Rs.1,644.15, with an intraday high of Rs.1,646.50 representing a 7.32% gain from the previous close. This rally outpaced the Sensex’s modest 0.30% gain and the Specialty Chemicals sector’s performance, highlighting selective buying interest. The stock traded above its 20-day, 50-day, 100-day, and 200-day moving averages, signalling medium- to long-term strength despite remaining below the 5-day average. Technical indicators such as MACD, Bollinger Bands, and KST supported the positive momentum, while the Dow Theory remained cautiously mixed. This day marked a key turning point, reversing the prior day’s weakness.
Our latest weekly pick is live! This Large Cap from Diamond & Gold Jewellery comes with clear entry and exit targets. See the detailed report with target price now!
- - Clear entry/exit targets
- - Target price revealed
- - Detailed report available
17 September 2026: Upgrade to Buy on Strong Financial and Technical Momentum
Following the strong rebound, MarketsMOJO upgraded Tatva Chintan Pharma Chem Ltd’s Mojo Grade from Hold to Buy on 16 September, reflecting improved financial results and technical indicators. The company reported a remarkable 54.84% growth in net profit for Q1 FY26-27, with PAT reaching Rs.16.98 crores, a 61.5% increase over the previous four-quarter average. PBDIT hit a record Rs.32.30 crores, and PBT excluding other income rose 47.0% to Rs.19.65 crores. The company’s low debt-to-equity ratio of 0.08 times underscores financial prudence. Despite a relatively high valuation with ROCE at 6.3% and EV/Capital Employed at 4.4, the stock trades at a discount to peers and maintains a low PEG ratio of 0.1, reflecting undervaluation relative to rapid profit growth.
Technically, the stock’s trend shifted from mildly bullish to bullish, supported by bullish MACD, Bollinger Bands, KST, and daily moving averages. OBV readings indicated accumulation, while the Dow Theory remained mixed with weekly bearish and monthly bullish signals. The stock closed at Rs.1,644.15, up 6.36%, approaching its 52-week high of Rs.1,838.85. This upgrade highlights the company’s strong earnings momentum and improving technical profile amid a challenging market backdrop.
18 September 2026: Continued Gains Close Week on a Positive Note
On the final trading day of the week, Tatva Chintan Pharma Chem Ltd extended its gains by 3.83%, closing at Rs.1,769.40. This marked the highest closing price of the week and capped a 10.20% weekly increase, significantly outperforming the Sensex’s 0.41% decline. The stock’s volume of 3,896 shares reflected sustained investor interest. Technical indicators remained supportive, with bullish momentum intact across multiple timeframes. The stock’s resilience amid broader market softness underscores its selective strength within the specialty chemicals sector.
Want to dive deeper on Tatva Chintan Pharma Chem Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Weekly Price Performance: Tatva Chintan vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-09-15 | Rs.1,545.80 | -3.73% | 35,169.62 | -1.69% |
| 2026-09-16 | Rs.1,644.15 | +6.36% | 35,276.25 | +0.30% |
| 2026-09-17 | Rs.1,704.20 | +3.65% | 35,439.31 | +0.46% |
| 2026-09-18 | Rs.1,769.40 | +3.83% | 35,625.23 | +0.52% |
Key Takeaways
Positive Signals: Tatva Chintan demonstrated strong earnings growth with a 54.84% net profit increase in Q1 FY26-27 and record PBDIT levels, underpinning the recent upgrade to a Buy rating. The stock’s technical indicators shifted decisively to bullish, supported by MACD, Bollinger Bands, KST, and OBV, signalling sustained momentum. The 10.20% weekly gain significantly outperformed the Sensex’s decline, reflecting selective strength in a challenging market.
Cautionary Notes: Despite recent gains, the stock experienced a sharp decline on 15 September amid mixed technical signals, including mildly bearish Dow Theory and weekly OBV readings. Valuation remains relatively expensive with a modest ROCE of 6.3% and a slight negative trend in operating profit over five years. The weekly Dow Theory’s mildly bearish stance suggests potential short-term volatility. Investors should remain vigilant to these factors amid the stock’s small-cap volatility.
Conclusion
Tatva Chintan Pharma Chem Ltd’s week was characterised by a strong recovery from early weakness, culminating in a 10.20% gain that outpaced the broader market. The upgrade to a Buy rating by MarketsMOJO reflects confidence in the company’s robust quarterly financials and improving technical momentum. While valuation and some technical signals counsel caution, the stock’s performance within the specialty chemicals sector highlights its resilience and potential for further gains. Investors should monitor ongoing earnings trends and technical developments to gauge sustainability of this positive momentum.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
